Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston
boston blog main
boston top stories
life sciences
national blog main
alnylam pharmaceuticals
drugs
fda
national top stories
patisiran
akcea therapeutics
biotech
clinical trials
hereditary transthyretin amyloidosis
inotersen
new york blog main
new york top stories
onpattro
rna interference
san diego blog main
san diego top stories
tafamidis
acute hepatic porphyrias
akin akinc
aminolevulinic acid
barry greene
biopharma
boston university
dan ollendorf
deals
duchenne
europe blog main
europe top stories
european medicines agency
givosiran
harvard pilgrim health care
institute for clinical and economic review
john berk
licensing
m&a
What
fda
4
×
medicine
rna
4
×
alnylam
ago
approval
drug
gene
historic
interference
rnai
second
uses
approve
approves
awaits
betting
billion
biological
biopharma
cells
crossed
deal
decades
decision
discovered
duchenne
ema
employ
europe
fingers
follows
friday
harmful
hits
indicated
make
method
mute
nod
Language
unset
Current search:
rna
×
fda
×
@xconomy.com
4 years ago
Roche Puts Up Historic $1.15B for Sarepta Duchenne Gene Therapy Deal
@xconomy.com
5 years ago
Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug
@xconomy.com
5 years ago
RNAi Hits Europe as EMA Follows FDA, Approves Alnylam Drug
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision